These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 30353318)

  • 41. [Chronic kidney disease (CKD) and bone. Regulation of calcium and phosphate metabolism by FGF23/Klotho].
    Fukumoto S
    Clin Calcium; 2009 Apr; 19(4):523-8. PubMed ID: 19329831
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [New Developments in CKD-MBD. Why is phosphate overload harmful?].
    Kuroo M
    Clin Calcium; 2014 Dec; 24(12):1785-92. PubMed ID: 25423923
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A review of ferric citrate clinical studies, and the rationale and design of the Ferric Citrate and Chronic Kidney Disease in Children (FIT4KiD) trial.
    Hanudel MR; Laster ML; Portale AA; Dokras A; Quigley RP; Guzman GAL; Zaritsky JJ; Hayde NA; Kaskel FJ; Mitsnefes MM; Ramirez JA; Imani PD; Srivaths PR; Kogon AJ; Denburg MR; Blydt-Hansen TD; Reyes LZ; Greenbaum LA; Weidemann DK; Warady BA; Elashoff DA; Mendley SR; Isakova T; Salusky IB
    Pediatr Nephrol; 2022 Nov; 37(11):2547-2557. PubMed ID: 35237863
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Elevated FGF23 and disordered renal mineral handling with reduced bone mineralization in chronically erythropoietin over-expressing transgenic mice.
    Daryadel A; Natale L; Seebeck P; Bettoni C; Schnitzbauer U; Gassmann M; Wagner CA
    Sci Rep; 2019 Oct; 9(1):14989. PubMed ID: 31628396
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fibroblast Growth Factor 23: Mineral Metabolism and Beyond.
    Grabner A; Mazzaferro S; Cianciolo G; Krick S; Capelli I; Rotondi S; Ronco C; La Manna G; Faul C
    Contrib Nephrol; 2017; 190():83-95. PubMed ID: 28535521
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Crosstalk of fibroblast growth factor 23 and anemia-related factors during the development and progression of CKD (Review).
    Zhang R; Wang SY; Yang F; Ma S; Lu X; Kan C; Zhang JB
    Exp Ther Med; 2021 Oct; 22(4):1159. PubMed ID: 34504604
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Laboratory abnormalities in CKD-MBD: markers, predictors, or mediators of disease?
    Evenepoel P; Rodriguez M; Ketteler M
    Semin Nephrol; 2014 Mar; 34(2):151-63. PubMed ID: 24780470
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bone kidney interactions.
    Nickolas TL; Jamal SA
    Rev Endocr Metab Disord; 2015 Jun; 16(2):157-63. PubMed ID: 26156535
    [TBL] [Abstract][Full Text] [Related]  

  • 49. FGF23 at the crossroads of phosphate, iron economy and erythropoiesis.
    Edmonston D; Wolf M
    Nat Rev Nephrol; 2020 Jan; 16(1):7-19. PubMed ID: 31519999
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lipocalin-2: a novel link between the injured kidney and the bone.
    Courbon G; David V
    Curr Opin Nephrol Hypertens; 2022 Jul; 31(4):312-319. PubMed ID: 35727169
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Beyond mineral metabolism, is there an interplay between FGF23 and vitamin D in innate immunity?
    Bacchetta J; Salusky IB; Hewison M
    Pediatr Nephrol; 2013 Apr; 28(4):577-82. PubMed ID: 23117582
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Associations Between Intravenous Iron, Inflammation and FGF23 in Non-Dialysis Patients with Chronic Kidney Disease Stages 3-5.
    Muras-Szwedziak K; Nowicki M
    Kidney Blood Press Res; 2018; 43(1):143-151. PubMed ID: 29444509
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of fibroblast growth factor 23 and Klotho in uremic cardiomyopathy.
    Grabner A; Faul C
    Curr Opin Nephrol Hypertens; 2016 Jul; 25(4):314-24. PubMed ID: 27219043
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New insights into the FGF23-Klotho axis.
    Olauson H; Vervloet MG; Cozzolino M; Massy ZA; Ureña Torres P; Larsson TE
    Semin Nephrol; 2014 Nov; 34(6):586-97. PubMed ID: 25498378
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fibroblast growth factor 23 is upregulated in the kidney in a chronic kidney disease rat model.
    Sugiura H; Matsushita A; Futaya M; Teraoka A; Akiyama KI; Usui N; Nagano N; Nitta K; Tsuchiya K
    PLoS One; 2018; 13(3):e0191706. PubMed ID: 29518087
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [CKD-MBD as a predictor of mortality].
    Hamano T
    Nihon Jinzo Gakkai Shi; 2014; 56(8):1233-42. PubMed ID: 25551984
    [No Abstract]   [Full Text] [Related]  

  • 57. FGF23 and Klotho in chronic kidney disease.
    Olauson H; Larsson TE
    Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):397-404. PubMed ID: 23666415
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease.
    Graciolli FG; Neves KR; Barreto F; Barreto DV; Dos Reis LM; Canziani ME; Sabbagh Y; Carvalho AB; Jorgetti V; Elias RM; Schiavi S; Moysés RMA
    Kidney Int; 2017 Jun; 91(6):1436-1446. PubMed ID: 28318623
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of klotho deletion from bone during chronic kidney disease.
    Kaludjerovic J; Komaba H; Lanske B
    Bone; 2017 Jul; 100():50-55. PubMed ID: 28232146
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Stimulation of fibroblast growth factor 23 by metabolic acidosis requires osteoblastic intracellular calcium signaling and prostaglandin synthesis.
    Krieger NS; Bushinsky DA
    Am J Physiol Renal Physiol; 2017 Oct; 313(4):F882-F886. PubMed ID: 28298360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.